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HHV-6B infection inhibits cell proliferation in G2/M, but no protein has so far been recognized to exert
this function. Here we identify the protein product of direct repeat 6, DR6, as an inhibitor of G2/M
cell-cycle progression. Transfection of DR6 reduced the total number of cells compared with mock-
transfected cells. Lentiviral transduction of DR6 inhibited host cell DNA synthesis in a p53-independent
manner, and this inhibition was DR6 dose-dependent. A deletion of 66 amino acids from the N-terminal
part of DR6 prevented efﬁcient nuclear translocation and the ability to inhibit DNA synthesis. DR6-
induced accumulation of cells in G2/M was accompanied by an enhanced expression of cyclin B1 that
accumulated predominantly in the cytoplasm. Pull-down of cyclin B1 brought down pCdk1 with the
inactivating phosphorylation at Tyr15. Together, DR6 delays cell cycle with an accumulation of cells in
G2/M and thus might be involved in HHV-6B-induced cell-cycle arrest.
& 2014 Elsevier Inc. All rights reserved.
1. Introduction
Inhibition of host cell cycle in G2/M is a well-known strategy
used by both RNA and DNA viruses. Although the consequences for
the viral infection are not always clear, inhibition of the G2/M
checkpoint has been suggested to increase the viral genome copy
number of some DNA viruses (Davy and Doorbar, 2007). The
strategies used to accomplish cell cycle arrest are diverse among
even closely related viruses, suggesting that the functional phe-
notype has been important during viral evolution. Despite the
different strategies, several of them converge on inhibiting the
cyclin B–Cdk1 complex (De Bolle et al., 2004; Li et al., 2011).
Parvovirus genomes activate ATM or ATR, or both, resulting in
phosphorylation of the Chk1 and Chk2 kinases (Luo et al., 2011).
This maintains the phosphatase Cdc25 in a phosphorylated and
inactivated state, which results in an inactive cyclin B–Cdk1
complex. An inactive cyclin B–Cdk1 complex is also a hallmark
of G2/M arrest observed during infection with the polyomavirus
SV40 (Yuan et al., 2003), or by the presence of viral proteins like
Vpr or Vif from HIV-1 (Kino et al., 2005; Sakai et al., 2011), E4 from
HPV-16 (Davy et al., 2005), NS1 from parvovirus (Wan et al., 2010),
and s1s from reovirus (Poggioli et al., 2000). Despite the G2/M-
arrested phenotype being well documented, the speciﬁc mechan-
isms remain to be deﬁned.
From the perspective of viral evasion, an additional advantage
of a G2/M arrest is the prevention of cell expansion, thereby
limiting the adaptive immune response towards the virus. Indeed,
ex vivo HIV-1-infected T cells are arrested in G2, which may limit
the host response towards HIV-1 (Zimmerman et al., 2006).
Infections by human herpesvirus (HHV)-6A and -6B are char-
acterized by relatively modest cellular immune responses towards
the viruses (Gerdemann et al., 2013) and both of these viruses
inhibit cell proliferation. HHV-6A infection blocks the cell cycle in
G2/M in SupT1, HSB2, human embryonic ﬁbroblasts and cord blood
mononuclear cells (De Bolle et al., 2004; Li et al., 2011, 2012;
Mlechkovich and Frenkel, 2007), whereas HHV-6B induces G2/M
arrest in SupT1 and MOLT3 cells (Mlechkovich and Frenkel, 2007;
Oster et al., 2005). A G1/S-phase arrest has also been observed
during HHV-6B infection in MOLT3 and HCT116 wt cells (Oster
et al., 2005; Oster et al., 2006). HHV-6A has been shown to alter
the E2F1/Rb pathway by inducing Rb degradation. Besides arrest-
ing the cell cycle this also results in elevated levels of the
transcription factor E2F1, which is active in transcribing genes
important for viral DNA synthesis, such as U27 and U79
(Mlechkovich and Frenkel, 2007; Sharon et al., 2014).
Inhibition of cell proliferation can occur through both p53-
dependent and -independent pathways (Nascimento et al., 2012).
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During HHV-6B infection, themajority of the cellular p53 is inactivated
and stabilized in the cytoplasm of the cell, most likely due to a
decrease in p53 degradation (Oster et al., 2005; Takemoto et al., 2004).
Although a minor fraction of p53 may be retained or redistributed to
the nucleus, p21 mRNA is not induced during HHV-6B infection (Oster
et al., 2008). In contrast, in p53 / cells, HHV-6B was still able to
inhibit cell-cycle progression, suggesting that a p53-independent
pathway is sufﬁcient to prevent G2/M transition.
Speciﬁc viral proteins mediating cell cycle arrest observed during
HHV-6B infection have not been identiﬁed. The HHV-6A and -6B
genomes are ﬂanked by direct repeats (DR). Alignments of the
dr6/dr7 gene locus from U1102, GS, HST, and Z29 indicate various
alternative splice and translation variants of dr6 and dr7 (Fig. 1A and
B). The HHV-6A (U1102) direct repeat (DR)7 protein, encoded by dr7
(1029 bp), originally identiﬁed as ORF-1, has been shown to bind and
inhibit p53 function and transform NIH-3T3 cells during transient
transfection (Kashanchi et al., 1997; Thompson et al., 1994). These
DR7-positive NIH-3T3 cells were oncogenic when injected into nude
mice (Kashanchi et al., 1997). Moreover, dr7(640 bp) from HST has
been cloned and its protein product was detected in Reed-Sternberg
cells of patients with Hodgkin’s lymphoma and was also shown to
bind p53 (Lacroix et al., 2010).
Here we report that the protein encoded by dr6 from HHV-6B has
the ability to inhibit G2/M transition. We demonstrate that this
function is p53-independent, but dependent on the N-terminal part
of the protein, which is also required for nuclear localization. This
identiﬁes the ﬁrst G2/M checkpoint-regulating protein in HHV-6B.
2. Results
2.1. DR6 inhibits cell proliferation
The dr6(1179 bp) product from HHV-6B (Fig. 1B) was cloned and
is referred to as DR6. Transient transfection of HCT116 wt cells with
DR6 gave rise to a 44 kDa band on immunoblotting when probed
with anti-DR6 antibodies, similar to what is detected during HHV-6B
infection (Fig. 1C). When DR6- and mock-transfected cell cultures
were counted over the following 72 h, a decline in the number of
DR6-transfected cells was observed within the ﬁrst 24 h (Fig. 1D).
These data demonstrated that overexpression of DR6 inhibited cell
proliferation and suggested that DR6 might be a viral protein arrest-
ing the cell-cycle progression.
2.2. DR6 suppresses DNA synthesis in HCT116 wt and
HCT116 p53 / cells
The observed decrease in the number of cells transiently trans-
fected with DR6 could be caused by a decrease in cell proliferation or
by induction of cell death. To increase DR6 expression efﬁciency,
HCT116 wt and p53 / cells were transduced with lentiviral
particles containing either the DR6 open reading frame or the ﬁreﬂy
luciferase (FLUC) open reading frame as a control. [3H]-thymidine
pulse for 4 h at 4, 24, 48, and 72 h post transduction (hpt) showed
reduced thymidine incorporation in DR6-transduced HCT116 wt cells
(Fig. 2A). Seventy-two hpt DR6-transduced cells showed approxi-
mately one-third [3H]-thymidine incorporation compared with
mock- or FLUC-transduced cells (Fig. 2A).
To examine whether the reduction in [3H]-thymidine incorpora-
tion was dependent upon p53, p53 / HCT116 cells were examined.
A similar pattern was observed in the absence of p53, indicating that
DR6 suppression of thymidine incorporation was independent of p53
(Fig. 2B). Decrease in the number of cells was not caused by cell
death as measured by ATP assay and PARP cleavage (data not shown).
DR6 and FLUC protein expression in HCT116 wt and p53 / cells was
veriﬁed by immunoblotting at 48 hpt (Fig. 2C and D).
2.3. DR6 suppresses DNA synthesis in a dose–response-dependent
manner
To be able to control the expression of DR6, the DR6 full-length
open reading frame was stably integrated in the Flp In™ T-Rex™ 293
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tetracycline-inducible expression cell system. GFP was used as a
control for protein expression. A four-fold tetracycline titration from
500 to 2 ng/ml showed an expected decrease in protein expression
on immunoblotting 48 h post tetracycline induction (hpti). DR6 and
GFP proteins were induced at tetracycline levels of 500–31 ng/ml;
however, between 31 and 7.8 ng/ml the protein expression shifts to a
minimal level, suggesting that the tetracycline repressor system is
slightly leaky (Fig. 3A). DR6 suppression of [3H]-thymidine incor-
poration correlated with tetracycline-induced expression of DR6 in a
dose-dependent manner (Fig. 3B). Compared with GFP at 48 hpti, the
[3H]-thymidine incorporation was reduced by approximately one-
third for cells treated with 500 or 125 ng/ml of tetracycline, by one-
fourth for cells treated with 31 ng/ml, and not reduced for cells
treated with only 7.8 or 2 ng/ml (Fig. 3B). This indicated that the
barely detectable DR6 levels at low tetracycline concentrations were
not functional in the [3H]-thymidine incorporation assay (Fig. 3A).
Based on the titration of tetracycline-induced expression, further
experiments with the Flp In™ T-Rex™ 293 system used a tetracycline
concentration of 100 ng/ml to ensure a level of DR6 expression that
was functional. [3H]-thymidine incorporation assays at 6, 24, 48, and
72 hpti on Flp In™ T-Rex™ 293-host, -GFP and -DR6 cells showed
the same pattern in host and GFP cells, independent of tetracycline
addition. As expected, DR6 cells showed a signiﬁcantly lowered [3H]-
thymidine incorporation at 48 h and 72 h upon tetracycline treat-
ment (Fig. 3C). These data further corroborated that the presence of
DR6 was sufﬁcient to prevent cell-cycle progression as measured by
[3H]-thymidine incorporation.
2.4. The N-terminal domain of DR6 is necessary for suppression
of DNA synthesis
To further study functional domains of DR6, we cloned a ΔN-
truncated version of DR6, termed DR6 ΔN, with a deletion of the
ﬁrst 198 bp except for ATG. DR6 ΔN has a 984 bp open reading
frame and an expected protein size of 37 kDa. Protein expression,
stability and molecular mass were conﬁrmed by immunoblotting
at 48 hpti with anti-DR6 antibody that recognizes the C-terminal
part of the protein (Fig. 4A).
A stably integrated DR6 ΔN in the Flp In™ T-Rex™ 293
tetracycline-inducible expression cell system was generated. From
cell lysates at 4, 24, 48, and 72 hpti, cytoplasmic (CY) and nuclear
extracts (NE) of DR6- and DR6 ΔN-tetracycline induced cells were
separated, immunoblotted and probed with anti-DR6 antibody.
Whereas DR6 was evenly distributed between the cytoplasm and
the nucleus, with a slight majority in the nucleus at 72 h, the vast
majority of the DR6ΔN protein localized to the cytoplasm with no
tendency towards nuclear translocation (Fig. 4B). When examined
by the [3H]-thymidine incorporation assay, DR6 ΔN protein was
unable to reduce [3H]-thymidine incorporation (Fig. 4C). These
observations strongly suggested that the N-terminal part of the
protein was necessary for efﬁcient nuclear localization and sup-
pression of cellular DNA synthesis.
2.5. DR6 expression delays the cell cycle progression in G2/M
To further address the question of which part of the cell cycle
was arrested by DR6, cell populations were separated in G0/G1-,
S- and G2/M-phases using Click-iTs EdU Alexa Fluors 488 Flow
Cytometry Assay Kit, which detects newly synthesized DNA, and
FxCycle™ Far Red stain, which stains the amount of DNA.
A schematic representation of the separations in the cell cycle
obtained by this method is shown in Fig. 5A, and the percentages
of Flp In™ T-Rex™ 293-host and –DR6 cell populations in each cell
cycle phase were determined at 24 and 48 hpti (Fig. 5B).
Cell cycle phases were plotted as phase indices with and
without induction of DR6, and DR6 ΔN expression (Fig. 5C).
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An increase in the percentage of cells in G2/M after 24 hpti was
detected in cells induced to express DR6. Host and DR6 ΔN cells
showed the same phase index pattern independent of tetracycline
treatment. This suggested that the effect observed for DR6 only
occurred when the protein was able to enter the nucleus. In the
time after accumulation of cells in the G2/M-phase, cells slowly
moved into the G0/G1-phase, which was seen as a slight decline in
the G2/M-phase index at 24–48 h and corresponded to a slight
increase in the G0/G1-phase index. Together, these data demon-
strated that DR6 expression caused a G2/M delay that subse-
quently gave rise to a reduced DNA synthesis.
2.6. DR6 expression enhances the formation of a cyclin B1–pCdk1
(Tyr15) complex
One of the essential events for G2/M transition is dephosphor-
ylation of pCdk1(Tyr15), which is in complex with cyclin B1.
During G2 arrest pCdk1(Tyr15) is bound to cyclin B1 and retained
in the cytoplasm to prevent initiation of mitosis. Therefore, we
examined cyclin B1 localization and cyclin B1–pCdk1(Tyr15)
complex status in DR6-expressing, G2/M-phase-delayed cells. Flp
In™ T-Rex™ 293-GFP and –DR6 cells were ﬁxed to coverslips and
treated with tetracycline at 4, 24, 48, and 72 h to induce G2/M-
phase delay. At 48 and 72 hpti cyclin B1 was more abundant in the
cytoplasm in DR6-expressing cells compared with untreated and
GFP-expressing cells (Fig. 6A) and this correlated with an increase
in cyclin B1 on immunoblotting (Fig. 6B). This suggested that the
G2/M-phase delay might be associated with an accumulation of
cyclin B1 in the cytoplasm. Furthermore, an increase in cyclin
B1–pCdk1(Tyr15) complex formation was seen after 48 hpti
(Figs. 6B and C). Pull-down of cyclin B1 showed increased cyclin
B1 levels in DR6-expressing cells. When cyclin B1 pull-down was
probed with anti-pCdk1(Tyr15) antibody, an increased amount of
pCdk1(Tyr15) protein was detected, indicative of increased asso-
ciation between the two proteins. Examination of lysates after
pull-down experiments indicated that a fraction of both cyclin B1
and pCdk1(Tyr15) was removed from the lysates compared with
the lysates prior to the pull-down experiments (data not shown).
This demonstrated that DR6 enhanced the accumulation of cyclin
B1–pCdk1(Tyr15), which represents an inactive form of cyclin B1.
3. Discussion
During DR6 overexpression a growth-promoting function, as
seen for DR7 from HHV-6A, might be expected. On the contrary,
a total cell count indicated a reduced cell proliferation of
DR6-transfected cells when compared with mock-transfected cells
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(Fig. 1B). Moreover, we were unable to demonstrate an association
between DR6 and p53 by either pull-down experiments or con-
focal microscopy co-localization analyses of cells overexpressing
DR6 and p53 during HHV-6B infection ((Schleimann et al., 2009)
and unpublished observations). In agreement with this, we
observed that DR6 suppressed DNA synthesis in a p53-inde-
pendent manner (Fig. 2). Alignments of the dr6/dr7 gene locus,
from U1102, GS, HST and Z29, indicate a variety of alternative
splice or translation variants, which may give rise to different
protein products. This could be a possible explanation for the
discrepancy between our data on DR6 and the previously pub-
lished data on DR7/ORF-1.
Generating an inducible DR6-expressing cell line allowed us to
demonstrate a dose–response effect of DR6 expression. This effect
appears to be speciﬁc for DR6, since it is not seen during induction
of an assumed irrelevant protein such as GFP. Nevertheless,
whether the DR6-induced cell-cycle arrest is a direct or an indirect
effect remains to be determined. DR7 has been characterized as a
transcription factor of HIV-LTR, and it is possible that the observed
effect is caused by transcription of one or more genes involved in
cell-cycle control (Kashanchi et al., 1994; Thompson et al., 1994).
Although DR6 clearly delays cell-cycle progression, we do not
know whether DR6 is critical for inhibiting cell proliferation
during HHV-6B infection. To address this we attempted to knock
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down DR6 using an ON-TARGETplus™ SMARTpool DR6 siRNA
(Dharmacon, Thermo Fisher Scientiﬁc, Lafayette, CO.). Unfortu-
nately, this did not signiﬁcantly reduce the level of DR6. Next, we
generated lentiviral particles expressing seven different DR6
shRNAs. However, these constructs were also insufﬁcient in knock-
ing down DR6. Thus, we were unable to demonstrate the sig-
niﬁcance of DR6 during HHV-6B infection. Nevertheless, the
localization of DR6 during overexpression is similar to its localiza-
tion during infection, suggesting that our data reﬂects the function
of DR6 during infection.
DR6 locates in replication compartments during HHV-6B infec-
tion (Schleimann et al., 2009), and inhibits cell proliferation when
overexpressed in several cell lines. DR6 delays cells in the G2/M-
phase with an accumulation of cyclin B1 in the cytoplasm and
causes an increase in cyclinB1–pCdk1(Tyr15) complex formation
(Figs. 5 and 6). These data are consistent with data showing G2/M-
phase arrest during HHV-6A and -6B infection (De Bolle et al.,
2004; Li et al., 2011; Oster et al., 2005). Li et al. have recently
shown that viral replication is enhanced when a G2/M arrest is
induced (Li et al., 2013) and this may occur by switching E2F1
towards transcription of viral genes (Sharon et al., 2014). Thus, a
possible role of DR6 during HHV-6B infection might be that DR6
functions as a chaperone facilitating the assembly of viral replica-
tion units or facilitating cell proliferation arrest in order to
enhance viral replication.
It appears that HHV-6A is not dependent on full-length DR6,
since deletion of the ﬁrst exon of DR6 does not prevent virus
replication in culture (Borenstein et al., 2010). The ﬁrst exon of
DR6 comprises 304 bp and we ﬁnd that a truncation of approxi-
mately two-thirds of this exon (198 bp) prevents translocation to
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the nucleus (Fig. 4B). We cannot exclude the possibility that DR6
might exert a function in the cytoplasm depending on the N-terminal
sequence; however, Fig. 4A indicates that the best inhibition is
achieved at 72 h where most of the DR6 have translocated to the
nucleus, consistent with the nuclear function of DR6. Although the
N-terminal part of DR6 might be necessary for G2/M delay in HHV-6B
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Fig. 6. DR6 expression induces accumulation of cyclin B1. (A) Confocal laser scanning microscopy of the localization of cyclin B1. Flp In™ T-REx™-293-GFP and -DR6 cells
were treated with and without tetracycline at 100 ng/ml. Cells were examined at 4, 24, 48, and 72 h post induction. DNA was stained with DAPI. A representative of two
experiments is shown. (B) and (C) Immunoblotting and band intensity quantiﬁcation of pull-down (PD). Pull-down was performed with anti-cyclin B1 antibody at 48 h post
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A representative of two experiments is shown.
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infections, it is not necessarily in conﬂict with the observation that
HHV-6A can still replicate.
DR6 does not encode a known nuclear localization motif. Thus,
the N-terminal part of the protein may contain a novel unknown
nuclear localization signal or may be necessary for protein–protein
interaction in the case of DR6 being transported to the nucleus
by an unknown cellular protein. Although a deletion may also
alter the conformation of a protein, the stability of the protein was
conﬁrmed by its presence in immunoblotting. Moreover, recogni-
tion of native DR6 ΔN can be achieved by an antibody raised
against a DR6 sequence. Anyhow, only crystallization data will
provide a deﬁnitive answer to whether DR6 ΔN may fold
differently.
In conclusion, we show that DR6 from HHV-6B (PL-1) delayed
cells in the G2/M-phase within the ﬁrst 24 h by a mechanism
independent of cellular p53 expression. The G2/M-phase delay was
accompanied by an accumulation of cyclin B1 and an increased
cyclin B1–pCdk1(Tyr15) complex formation. We speculate that
this delay in cell cycle is advantageous for viral genome produc-
tion and hence formation of new viral particles.
4. Materials and methods
4.1. Cell lines and virus stock
The human epithelial colon carcinoma cell line HCT116 wt and
p53 / (a gift from B. Vogelstein and K.W. Kinzler, Johns Hopkins
University School of Medicine, Baltimore, MD, USA) was grown
in McCoy's medium (Gibco, CA, USA), supplemented with 10%
inactivated fetal calf serum (iFCS) (Sigma-Aldrich, Saint Louis,
USA), glutamine (0.2 g/l), HEPES (10 mM), penicillin (0.2 g/l),
and streptomycin (0.2 g/l) (all from the Substrate Department,
Bartholin Building, Aarhus University, Denmark).
Flp InTM T-RExTM 293 host cell line containing a stably integrated
FRT site (pFRT/lacZeo) and tetracycline repressor (pcDNA™6/TR)
was grown in Dulbecco's Modiﬁed Eagles Medium (DMEM), High
Glucose, GlutamaxTM, HEPES (Gibco) supplemented with 15% iFCS
(Sigma-Aldrich), penicillin (0.2 g/l), and streptomycin (0.2 g/l) (from
the Substrate Department, Aarhus University). To sustain the tetra-
cycline repressor site the cells are grown in 10 mg/ml Blasticidin (Life
Technologies, Carlsbad, CA, USA) and to sustain the Flp In site the
cells are grown in 100 mg/ml Zeocin (Life Technologies).
HHV-6B, strain PL1 (generated by Dr. P. Lusso, Milan, Italy), was
propagated as previously described (Schleimann et al., 2009). Viral
titer was determined by the Reed-Muench assay to 3200 TCID50.
4.2. Cloning of DR6 and DR6ΔN
The Direct Repeat 6 full-length gene (DR6) was cloned into the
pcDNA™3.1D/V5-His-TOPO (Life Technologies) vector using forward
primer: 50-caccatgacaacgcgacacacgcag-30 and reverse primer: 50-
ctaatccaggtacgctctttg-30. This vector is referred to as pcDNA3.1-DR6.
Furthermore, dr6 was cloned into a third-generation lentiviral
packaging vector (pCCL-WPS-PGK-GFIP-WHV) and pcDNA™5/FRT/
TO vector using forward primer: 50- atgacaacgcgacacacgcag-30 and
reverse primer: 50-ctaatccaggtacgctctttg-30. These vectors are referred
to as pCCL-DR6 and pcDNA™5/FRT/TO-DR6. Insertion into the
vectors was performed using restriction enzymes XbaI, ApaI and
Quick Ligation™ kit (New England Biolabs (NEB), Ipswich, MA) for
pCCL-DR6 and HindIII and ApaI and Quick Ligation™ kit (NEB) for
pcDNA™5/FRT/TO-DR6. In addition, a DR6-truncated version (DR6
ΔN) was generated by PCR using forward primer: 50- atggaactc-
catccggatccgta-30 and reverse primer: 50-ctaatccaggtacgctctttg-30. The
dr6 ΔN was cloned into the pcDNA™5/FRT/TO vector using HindIII
and ApaI and Quick Ligation™ kit (NEB) and referred to as
pcDNA™5/FRT/TO-DR6ΔN. All PCR reactions were carried out under
the same conditions with an initial heat shock starting at 95 1C for
5 min, after which 35 ampliﬁcation cycles were carried out with a
denaturation step at 94 1C for 30 s, a primer annealing step at 55 1C
for 30 s, and a ﬁnal elongation step at 68 1C for 60 s.
4.3. Production of lentiviral particles
For the production of lentiviral particles, 293T cells were
seeded at a density of 5104 cells/cm2 in 10-cm dishes 1 day
before transfection. Cells were transfected using 250 mM CaCl2
with 3.75 mg pMD.2G, 3 mg pRSV-Rev, 13 mg pMDGP-Lg/RRE, and
13 mg pCCL-DR6 or pCCL-FLUC. At 48 and 72 h after transfection
the viral supernatants were harvested and passed through 0.45 mm
ﬁlters to remove cellular debris (Sarstedt, Nümbrecht, Germany).
The resulting lentiviral particles were designated LV-DR6 and
LV-FLUC. The lentiviral supernatants were ultracentrifuged for
2 h (4 1C at 25,000 rpm) in a SW28 rotor (Beckman Coulter, CA,
USA). Virus pellets were re-suspended overnight in PBS at 4 1C in a
volume of 1/300 of the original volume.
4.4. Transduction of lentiviral particles
HCT116 wt and HCT116 p53 / cells were seeded at 3106
cells per ﬂask in a T25 cell culture ﬂask to obtain maximum
transduction efﬁciency at 80–90% conﬂuence the following day.
Cells were mock-, LV-FLUC- or LV-DR6-transduced and 8 mg/ml
polybrene in 5 ml culture medium. 4 h post transduction, an
additional 4 ml of medium was provided. 24 h post transduction,
the cells were seeded for further analyses.
4.5. Generation of the stably inducible Flp In™ T-REx™ 293-DR6,
-DR6 ΔN and -GFP cell lines
The pcDNA™5/FRT/TO-DR6, -DR6 ΔN and -GFP vectors were
each mixed with a recombinase containing vector (pOG44) in a 1:9
ratio and then Fugene-transfected into the Flp In™ T-REx™ 293
host cell. The next day the cells were split and the culture medium
was supplemented with 100 mg/ml hygromycin instead of Zeocin
to select cells that had integrated the DR6 gene. To induce DR6
protein expression cells were treated with 100 ng/ml tetracycline
(Sigma-Aldrich).
4.6. [3H]-Thymidine incorporation assay
For thymidine incorporation assay, cells were seeded at a
concentration of 2000 cells/200 ml per well in a 96-well ﬂat-
bottom plate. Cells were incubated at 37 1C in 4, 24, 48, or 72 h
including incubation with 1 mCi [3H]-thymidine/well (Perkin
Elmer, Waltham, MA, USA) for the last 4 h. Post incubation the
plates were stored at 20 1C until the cells were harvested and
the incorporated [3H]-thymidine was counted on a 1450 Micro-β-
scintillations counter (Perkin Elmer).
4.7. Cell lysis and immunoblotting
Cells were lysed for 30 min in 1 lysis buffer (Cell Signaling,
Technology Inc., Beverly, MA, USA) supplemented with 1 mM
phenylmethanesulphonylﬂuoride (PMSF), 5 mM sodium ﬂuoride
(NaF) and Complete Mini Protease Inhibitor (Roche Diagnostics, IN,
USA) according to the manufacturer’s recommendations. Lysates
were centrifuged at 4,200g for 5 min, followed by a 10 min
centrifugation at 20,000g to remove cell debris completely. Protein
concentrations of the lysates were measured by the Bradford
method and 30 mg protein of each lysate was separated on an XT
Criterion 10% gel (Bio-Rad, CA, USA) with 1 XT MOPS running
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buffer (Bio-Rad) for 1 h at 175 V (constant) and subsequently
electro-transferred to a nitrocellulose membrane at 300 mA (con-
stant) for 2 h.
Nuclear and cytoplasmic extracts were prepared from Flp In ™
T-REx™ 293-DR6 and -DR6 ΔN treated with or without 100 ng/ml
tetracycline to induce protein expression (ProteoExtract Subcellu-
lar Proteome Extraction Kit, Calbiochem, Merck, Darmstadt,
Germany).
The following antibodies were used for immunoblotting: mouse
anti-7c7 antibody (1:600) (Argene Biosoft, Verniolle, France); rabbit
anti-DR6 antibody (1:1000) (Genscript, Piscataway, NJ, USA) were
custom-made to the C-terminal 14 amino acid peptide from DR6, as
previously described in Schleimann et al. (2009); rabbit anti-GAPDH
antibody (1:2000) (Santa Cruz Biotechnology, CA, USA); rabbit anti-
GFP antibody (1:500) (Santa Cruz Biotechnology); goat anti-RCC1
antibody (1:500) (Santa Cruz Biotechnology); rabbit anti-cyclin B1
antibody (1:1000 in 5% BSA in 1 TBS/0.1% Tween20) (Cell Signal-
ing); rabbit anti-pCdc2(Tyr15) antibody (1:1000 in 5% BSA in
1 TBS/0.1% Tween20) (Cell Signaling); horseradish peroxidase-
conjugated polyclonal swine anti-rabbit antibody (P0217); and horse-
radish peroxidase-conjugated polyclonal rabbit anti-mouse antibody
(P0260) (all from Dako, Glostrup, Denmark). All of the peroxidase-
conjugated antibodies were used at 1:2000 dilution in 5% skimmed
milk or 5% BSA in TBS with 0.1% Tween 20 (Sigma-Aldrich).
Membranes were developed with Chemiluminescence femto (Pierce,
Thermo Scientiﬁc, IL, USA) and Image Reader Las-4000 (Science
Imaging Scandinavia AB, Sweden).
4.8. Cell cycle assay
Using Click-iTs EdU Alexa Fluors 488 Flow Cytometry Assay
Kit (Life Technologies) and FxCycle™ Far Red stain (Life Technol-
ogies) cell populations were separated in G0/G1-, S- and G2/M-
phases. Flp In™ T-REx™ 293-host, –GFP, or –DR6 cells were
seeded in T25 culture ﬂasks with or without 100 ng/ml tetracy-
cline and incubated at 37 1C in 2, 24, 48, or 72 h including 10 mM
EdU during the last 2 h of incubation. EdU (5-ethynyl-20-deoxyur-
idine) is a thymidine analog modiﬁed with an ethynyl moiety with
an alkyne. Cells were ﬁxed, permeabilized, and treated with Alexa
Flours 488 coupled to azide, which reacts with the alkyne. Finally,
cells were treated with FxCycle™, a DNA stain, according to
manufacturer’s guidelines. Cell cycle analyses were performed on
an FC500 ﬂow cytometer (Beckman-Coulter).
4.9. Confocal microscopy
Flp In™ T-REx™ 293-GFP or –DR6 was transferred to poly-L-
lysine-coated slides and incubated with or without 100 ng/ml
tetracycline for 4, 24, 48, and 72 h followed by ﬁxation in 4%
formalin/PBS (pH 7.5). Cells were washed twice in PBS, permeabi-
lized in 0.2% Triton X-100 (Sigma-Aldrich)/PBS and blocked in 5%
BSA (Sigma-Aldrich)/PBS. Cyclin B1 was visualized using rabbit
anti-cyclin B1 antibody (Cell Signaling) (1:200) and the secondary
antibody was a goat anti-rabbit F(ab0)2 antibody conjugated with
Alexa Fluor 488 (Life Technologies) (1:400). Nuclear staining was
performed with the DNA dye 49, 6-diamidino-2-phenylindole
dihydrochloride (DAPI), (Sigma-Aldrich). For imaging, a 488 nm
line of a multiline argon laser, and the 633 nm line of the helium–
neon laser on a confocal laser scanning microscope (LSM710, Zeiss,
Jena, Germany) were used with a 63 oil-immersion objective
with a numerical aperture of 1.4.
4.10. Pull-down assay
Flp In™ T-REx™ 293-GFP or –DR6 cells were seeded in T75
culture ﬂasks with or without tetracycline at a concentration of
100 ng/ml for 48 h. Cells were washed once with PBS and lysed
directly in the incubation ﬂask in 1 ml of a 1% CHAPS lysis buffer
supplemented with 1 mM sodium orthovanadate (Na2VO4), 1 mM
phenylmethanesulphonylﬂuoride (PMSF), 5 mM sodium ﬂuoride
(NaF) and Complete Mini Protease Inhibitor (Roche Diagnostics)
according to the manufacturer’s recommendations. Lysates were
centrifuged at 20,000g for 15 min to remove cell debris. Antibody
crosslinking to beads was prepared from 3 mg rabbit cyclin B1
antibody (Cell Signaling) or 3 mg control rabbit IgG (Cell lab,
Beckman-Colter) coupled to 30 ml protein A Dynabeads (Life
Technologies). The mixture was rotated for 1 h at 4 1C, washed
twice in PBS and antibodies were cross-linked to beads using
7.5 mg/ml dimethyl pimelimidate (DMP) pH 8.5 (Sigma-Aldrich)
for 30 min at room temperature (RT). DMP-crosslinking was
repeated three times separated by 5 min washes in 0.2 M trietha-
nolamine in PBS at RT, after which the cross-linking was quenched
twice using 50 mM ethanolamine in PBS for 5 min at RT. Remain-
ing non-cross-linked antibody was eluted with 1 M glycine. Elu-
tion was performed twice for 10 min at RT. The mixture was
washed three times with 1% CHAPS buffer for 5 min at RT. Finally
the antibody-conjugated beads were incubated with 1 ml of
protein lysate overnight at 4 1C, followed by 3 washing steps in
PBS. Bound protein was eluted with 5 volumes of 4 sample
buffer (Bio-Rad) and 1 volume of reducing agent (Bio-Rad).
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